#United States #New Orleans #Nordic Pharma #LACRIFILL #SEVER Life Sciences

Revolutionary Treatment for Ocular Surface Control: LACRIFILL

Nordic Pharma, Inc., a subsidiary of SEVER Life Sciences B.V., is shedding light on a novel ocular treatment ahead of the American Academy of Ophthalmology (AAO) conference 2026, scheduled to take place in New Orleans from October 9 to 12. The focal point of this presentation is LACRIFILL® Canalicular Gel, an innovative therapy aimed at enhancing ocular surface management.

With its growing usage across more than 2,200 ophthalmology and optometry practices throughout the United States, LACRIFILL has made significant strides in ophthalmic care, particularly for patients undergoing cataract or refractive surgery. This gel has also emerged as a vital support for those suffering from dry eye symptoms, having positively impacted over 130,000 patients.

Recent surveys conducted regarding patient experiences highlight the efficacy of LACRIFILL, with 96% of cataract surgery patients within the last six months reporting relief from discomfort when using the gel, alongside 91% among all surveyed patients. "These statistics reflect the growing confidence in LACRIFILL's ability to enhance patient comfort and satisfaction," commented Dr. Jai G. Parekh, MBA, Nordic Pharma's commercial director.

The AAO conference serves as a pivotal platform for eye care professionals to engage with the latest advancements in ophthalmology and their implications for patient outcomes. "We are excited to share concrete data demonstrating the benefits of LACRIFILL, including increased comfort and stabilized vision post-surgery, as well as its role in alleviating dryness that often leads to a reduced dependency on both prescription and over-the-counter eye drops," Dr. Parekh added.

A notable testament comes from Dr. David Szynkarski of the Mann Eye Institute in Texas, revealing that 83% of patients who have had surgery in recent months and received LACRIFILL treatments reported a significant reduction in discomfort. This finding underscores the importance of monitoring the ocular surface following surgical interventions, which is crucial for postoperative recovery, enhancing patient satisfaction, and ultimately, their quality of life.

During the AAO salon, attendees visiting Nordic Pharma's booth (#3136) will observe firsthand demonstrations of LACRIFILL administration conducted by eye care professionals on Saturday, October 10, and Sunday, October 11, between 10 AM and 4 PM. Additionally, participants will have the opportunity to place orders directly at the booth.

For those interested in further details and ordering information about LACRIFILL, they should visit lacrifill.com.

About SEVER Life Sciences B.V.

SEVER Life Sciences is an international private pharmaceutical holding company dedicated to enhancing well-being across the globe. Headquartered in the Netherlands, it encompasses three distinct yet complementary entities, offering a broad spectrum of products, pharmaceutical development services, and administration technologies.

About Nordic Pharma, Inc.

As a subsidiary of SEVER Life Sciences B.V., Nordic Pharma, Inc. collaborates with well-established global biopharmaceutical companies, uniquely positioning itself to leverage its expertise in marketing sterile medical devices and products.

Disclaimer

This release includes forward-looking statements. These statements reflect SEVER Life Sciences / Nordic Pharma’s current outlook and beliefs regarding future events. Given inherent uncertainties in the marketplace and regulatory environment, actual results may differ significantly. SEVER Life Sciences / Nordic Pharma disclaims any obligation to update such statements due to new information or future occurrences. For inquiries, please contact Nordic Pharma, Inc. at [email protected]